139 related articles for article (PubMed ID: 30941698)
1. The Cancer Drugs Fund in Practice and Under the New Framework.
Sabry-Grant C; Malottki K; Diamantopoulos A
Pharmacoeconomics; 2019 Jul; 37(7):953-962. PubMed ID: 30941698
[TBL] [Abstract][Full Text] [Related]
2. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.
Aggarwal A; Fojo T; Chamberlain C; Davis C; Sullivan R
Ann Oncol; 2017 Aug; 28(8):1738-1750. PubMed ID: 28453615
[TBL] [Abstract][Full Text] [Related]
3. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund.
Leigh S; Granby P
Value Health; 2016; 19(5):567-76. PubMed ID: 27565274
[TBL] [Abstract][Full Text] [Related]
4. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L; Wordsworth S; Schuh A; Middleton MR; Rees S; Barker RW
BMC Health Serv Res; 2018 May; 18(1):393. PubMed ID: 29855313
[TBL] [Abstract][Full Text] [Related]
5. Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales.
Chamberlain C; Collin SM; Stephens P; Donovan J; Bahl A; Hollingworth W
Br J Cancer; 2014 Oct; 111(9):1693-702. PubMed ID: 24569469
[TBL] [Abstract][Full Text] [Related]
6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
7. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
Morrell L; Wordsworth S; Fu H; Rees S; Barker R
BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927
[TBL] [Abstract][Full Text] [Related]
8. An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund.
Trigg LA; Barnish MS; Hayward S; Shaw N; Crathorne L; Groves B; Spoors J; Strong T; Melendez-Torres GJ; Farmer C
Pharmacoecon Open; 2024 Mar; 8(2):303-311. PubMed ID: 38087151
[TBL] [Abstract][Full Text] [Related]
9. "What's fair to an individual is not always fair to a population": A qualitative study of patients and their health professionals using the Cancer Drugs Fund.
Chamberlain C; Owen-Smith A; MacKichan F; Donovan JL; Hollingworth W
Health Policy; 2019 Aug; 123(8):706-712. PubMed ID: 31279588
[TBL] [Abstract][Full Text] [Related]
10. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.
Linley WG; Hughes DA
Health Econ; 2013 Aug; 22(8):948-64. PubMed ID: 22961976
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
12. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
13. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
14. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
15. Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Jones-Hughes T; Dunham J; Warren FC; Robinson S; Stephens P; Hoyle M
Pharmacoeconomics; 2018 Jan; 36(1):39-49. PubMed ID: 28914440
[TBL] [Abstract][Full Text] [Related]
16. Reimbursement of targeted cancer therapies within 3 different European health care systems.
Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
[TBL] [Abstract][Full Text] [Related]
17. MPs find no evidence that Cancer Drugs Fund was spent wisely.
Hawkes N
BMJ; 2016 Feb; 352():i755. PubMed ID: 26850036
[No Abstract] [Full Text] [Related]
18. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
19. Did It Matter That the Cancer Drugs Fund Was Not NICE? A Retrospective Review.
Dixon P; Chamberlain C; Hollingworth W
Value Health; 2016; 19(6):879-884. PubMed ID: 27712717
[TBL] [Abstract][Full Text] [Related]
20. New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
Mayor S
BMJ; 2016 Feb; 352():i1208. PubMed ID: 26926879
[No Abstract] [Full Text] [Related]
[Next] [New Search]
